Drug Profile
Research programme: anticancer therapeutics - Endo/Orion
Latest Information Update: 01 Nov 2013
Price :
$50
*
At a glance
- Originator Endo Pharmaceuticals; Orion
- Class
- Mechanism of Action Androgen receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Prostate cancer